



JIM GIBBONS
Governor

STATE OF NEVADA
DEPARTMENT OF HUMAN RESOURCES
DIVISION OF HEALTH CARE FINANCING AND POLICY
NEVADA MEDICAID

MICHAEL J. WILLDEN
Director

CHARLES DUARTE
Administrator

NOTICE OF OPEN PUBLIC MEETING

The Division of Health Care Financing and Policy (DHCFP) Pharmacy and Therapeutics Committee will conduct a public meeting on **June 24, 2010**, beginning at **1:00 p.m.** at the following location:

**Las Vegas Chamber of Commerce
6671 Las Vegas Blvd. S., Suite 300
Las Vegas, NV 89119**

Some members will be attending the meeting via video conference at First Health Services, 885 Trademark Dr. Reno, NV 89521. Public seating is limited.

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Rita Mackie at: 775-684-3681 or email rmackie@dhcp.nv.gov in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

Below is an agenda of all items scheduled to be considered. Unless otherwise noted, items may be taken out of order at the discretion of the Chairperson.

Public comment is limited to 5 minutes per individual, organization, or agency, but may be extended at the discretion of the Chairperson.

AGENDA

- I. Call to Order and Roll Call
- II. *Review and Approval of the May 3, 2010 Meeting Minutes
- III. New Drug Class Reviews
 - A. Analgesics: Topical
 1. Public Comment
 2. Drug Class Review Presentation – First Health Services
 3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Populations
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL
 - B. Analgesics: Tramadol Containing Products
 1. Public Comment
 2. Drug Class Review Presentation – First Health Services
 3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

IV. Established Drug Class Reviews

A. Intranasal Rhinitis Agents

1. Public Comment
2. Drug Class Review Presentation – First Health Services
3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

B. Growth Hormone Agents

1. Public Comment
2. Drug Class Review Presentation – First Health Services
3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

C. Respiratory: Long Acting Beta Adrenergics

1. Public Comment
2. Drug Class Review Presentation – First Health Services
3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

V. ANNUAL REVIEW – DRUG CLASSES BEING REVIEWED DUE TO RELEASE OF NEW DRUGS

A. Analgesics: Long-Acting narcotics Public Comment

1. Public Comment
2. Drug Class Review Presentation – First Health Services
3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

B. Central Nervous System: Sedative Hypnotics

1. Public Comment
2. Drug Class Review Presentation – First Health Services
3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

- C. Immunomodulators: Injectable
 - 1. Public Comment
 - 2. Drug Class Review Presentation – First Health Services
 - 3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - 5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

- D. Antiparkinson's Agents: Non-ergot Dopamine Agonists
 - 1. Public Comment
 - 2. Drug Class Review Presentation – First Health Services
 - 3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - 5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

- E. Anaphylaxis: Self-Injectable Epinephrine
 - 1. Public Comment
 - 2. Drug Class Review Presentation – First Health Services
 - 3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - 5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

- F. Ophthalmic Antihistamines
 - 1. Public Comment
 - 2. Drug Class Review Presentation – First Health Services
 - 3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - 5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

- G. Multiple Sclerosis Agents
 - 1. Public Comment
 - 2. Drug Class Review Presentation – First Health Services
 - 3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - 5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

- H. Cardiovascular: Calcium Channel Blockers & Combinations
 - 1. Public Comment
 - 2. Drug Class Review Presentation – First Health Services
 - 3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - 5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

- I. Direct Renin Inhibitors
 - 1. Public Comment
 - 2. Drug Class Review Presentation – First Health Services
 - 3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - 5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

- J. Otic Fluoroquinolones
 - 1. Public Comment
 - 2. Drug Class Review Presentation – First Health Services
 - 3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - 5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

- K. Urinary Tract Antispasmodics
 - 1. Public Comment
 - 2. Drug Class Review Presentation – First Health Services
 - 3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - 5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

- VI. ANNUAL REVIEW – Drug Classes without Proposed Changes
 - A. Public Comment
 - B. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy without Changes
 - 1. Acne Agents: Topical: Retinoid Agents and Combinations
 - 2. Acne Agents: Topical: Benzoyl Peroxide and Clindamycin Combinations
 - 3. Alzheimer’s Agents
 - 4. Androgenic Agents: topical
 - 5. Antibiotics: Cephalosporins 2nd Generation
 - 6. Antibiotics: Cephalosporins 3rd Generation
 - 7. Antibiotics: Macrolides
 - 8. Antibiotics: Quinolones 2nd Generation
 - 9. Antibiotics: Quinolones 3rd Generation
 - 10. Anticoagulants: Injectable
 - 11. Antidepressants: SSRIs
 - 12. Antidepressants Other

13. Antiemetics: Oral, 5-HT₃s
14. Antifungals: Onychomycosis Agents
15. Antihistamines: 2nd Generation
16. Anti-Migraine Agents: Triptans
17. Benign Prostatic Hyperplasia (BPH) Agents: Alpha-blockers
18. Benign Prostatic Hyperplasia (BPH) Agents: 5-alpha-reductase Inhibitors
19. Bone Ossification Agents: Bisphosphonates
20. Cardiovascular: ACE Inhibitors & Diuretic Combinations
21. Cardiovascular: Angiotensin II Receptor Blockers & Diuretic Combinations
22. Cardiovascular: Antihyperlipidemics: Bile Acid Sequestrants
23. Cardiovascular: Antihyperlipidemics: Cholesterol Absorption Inhibitors
24. Cardiovascular: Antihyperlipidemics: Statins & Statin Combinations
25. Cardiovascular: Antihyperlipidemics: Niacin Agents
26. Cardiovascular: Antihyperlipidemics: Triglyceride Lowering Agents
27. Cardiovascular: Beta Blockers
28. Central Nervous System: ADHD/Stimulants
29. Electrolyte Depleters
30. Erythropoiesis Stimulating Proteins
31. Gastrointestinal Agents: H₂Ras
32. Gastrointestinal Agents: PPIs
33. Gastrointestinal Agents: Ulcerative Colitis
34. Hepatitis C Agents
35. Herpetic Antiviral Agents
36. Herpetic Antiviral Agents : Topical
37. Immunomodulators: Topical
38. Impetigo Agents: Topical
39. Leukotriene Modifiers
40. Nasal Calcitonins
41. Ophthalmic Glaucoma Agents
42. Ophthalmic Non-Steroidal Anti-Inflammatory Agents
43. Ophthalmic Quinolones
44. Platelet Aggregation Inhibitors
45. Progestins for Cachexia
46. Psoriasis Agents: Topical
47. Pulmonary Arterial Hypertension Agents - Endothelin Receptor Antagonists
48. Respiratory: Inhaled Anticholinergic Agents
49. Respiratory: Inhaled Corticosteroids/Nebs
50. Respiratory: Short-Acting Beta Adrenergic -Inhalers/Nebs
51. Skeletal Muscle Relaxants

- C. *Committee Discussion and Approval of Drug Classes without changes for the PDL
- VII. Report by FHSC on New Drugs to Market, New Generic Drugs to Market, and New Line Extensions
- VIII. Review of Next Meeting Location, Date, and Time
- IX. Public Comment
- X. *Adjournment

***Denotes items, including subparts, on which an action may be taken.**

This notice and agenda has been posted on or before 9:00 a.m. on the third working day before the meeting at the following locations:

Notice of this meeting will be available on or after the posting date of this Agenda at the DHCFP Web site (dhcftp.state.nv.us).

Posting of the Agenda will be at the Nevada Medicaid Central offices in Carson City and Las Vegas; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the action items will be mailed to you or they may be reviewed Monday through Friday from 9:00 a.m. until 5:00 p.m., or at the meeting. Please call at least one day ahead for an appointment for document review. Written comments on the proposed changes may be sent to the DHCFP, 1100 E. William Street, Suite 102, Carson City, NV 89701.

All persons that have requested in writing to receive the Open Meeting Agenda have been duly notified by mail or e-mail.

Anyone presenting documents for consideration during the public comment portion of the meeting must provide sufficient copies for each member of the committee and the official record. Copies are to be distributed at the time of the meeting and should be provided at both meeting locations; DHCFP or its contractor will not distribute public comment information or materials prior to the public meeting.